Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The publication presents a phase II clinical trial evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer harboring specific genetic mutations.
The study demonstrates a significant improvement in progression-free survival compared to standard treatment, with a manageable safety profile.
These findings support the therapy as a promising option for this patient subgroup, warranting further investigation in larger, randomized trials.